Laurus Investment Counsel Inc. Has $14.61 Million Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Laurus Investment Counsel Inc. lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 10.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 79,150 shares of the medical research company’s stock after buying an additional 7,435 shares during the quarter. Charles River Laboratories International comprises about 7.5% of Laurus Investment Counsel Inc.’s holdings, making the stock its 5th largest position. Laurus Investment Counsel Inc. owned 0.15% of Charles River Laboratories International worth $14,611,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Wolff Wiese Magana LLC bought a new stake in shares of Charles River Laboratories International during the 3rd quarter worth $32,000. Versant Capital Management Inc boosted its position in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares during the last quarter. Assetmark Inc. increased its holdings in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares during the last quarter. Pinnacle Bancorp Inc. lifted its stake in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International in the 3rd quarter worth approximately $59,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $164.88 on Friday. Charles River Laboratories International, Inc. has a twelve month low of $159.65 and a twelve month high of $275.00. The business has a 50-day moving average price of $184.15 and a 200-day moving average price of $195.67. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The firm has a market cap of $8.43 billion, a price-to-earnings ratio of 20.64, a price-to-earnings-growth ratio of 6.13 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same period in the previous year, the firm posted $2.72 EPS. The business’s quarterly revenue was down 1.6% on a year-over-year basis. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 10.17 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group lowered their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. TD Cowen upped their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Redburn Atlantic started coverage on Charles River Laboratories International in a research note on Monday, October 14th. They issued a “sell” rating and a $151.00 price target on the stock. Evercore ISI increased their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. Finally, CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a report on Monday, November 18th. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and a consensus price target of $204.38.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).